About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Ohio | 20,938 Studies Near You | Clareo Health

Clinical Trials LocationsOhio

Clinical Trials in Ohio

Discover 20,938 clinical trials near Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 6861-6880 of 20,938 trials

COMPLETEDNA26 miles

Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers

NCT06053463

To explore the wear experience in Dailies TOTAL1 Multifocal contact lenses in presbyopic adults who have previously dropped out of contact lens wear.

Jennifer Fogt35 participantsStarted Oct 2023

Columbus, Ohio, United States • Granville, Ohio, United States

Active Not RecruitingPhase 1/232 miles

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Multiple Myeloma

Celgene424 participantsStarted Sep 2019

Denver, Colorado, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +46 more locations

Find Trials by Condition in Ohio

Breast Cancerin Ohio Lung Cancerin Ohio Prostate Cancerin Ohio Colorectal Cancerin Ohio Melanomain Ohio Leukemiain Ohio Lymphomain Ohio Pancreatic Cancerin Ohio Ovarian Cancerin Ohio Brain Cancerin Ohio Diabetesin Ohio

Data from ClinicalTrials.govTerms

Active Not Recruiting32 miles

MIRACLE of LIFE Study

NCT06074601

The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at greatest risk of developing adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)? 2. What is the performance of such biomarkers when predicting an adverse pregnancy outcome (e.g., sensitivity, specificity, PPV, NPV, TPR)?

Preterm LaborPreterm BirthPreterm Birth Complication+7 more

Mirvie10,000 participantsStarted Aug 2021

San Diego, California, United States • Orlando, Florida, United States • New Orleans, Louisiana, United States +7 more locations

RECRUITING32 miles

IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

NCT03536897

This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT). The primary aim is to determine the 5-year risk of in-breast tumor recurrence. Secondary aims include identification of acute- and late-toxicity, cosmetic result, disease-free survival and overall survival.

Mount Carmel Health System168 participantsStarted Feb 2018

Columbus, Ohio, United States

COMPLETEDPhase 387 miles

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922

The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).

Mild Cognitive Impairment (MCI)Alzheimer Disease

Eli Lilly and Company148 participantsStarted Nov 2021

Fullerton, California, United States • Irvine, California, United States • Sherman Oaks, California, United States +28 more locations

COMPLETEDPhase 395 miles

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025

The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

Short Bowel Syndrome

VectivBio AG164 participantsStarted Jan 2021

Los Angeles, California, United States • Naples, Florida, United States • Chicago, Illinois, United States +65 more locations

RECRUITING140 miles

Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation

NCT05008185

This study is being done to demonstrate the effectiveness of Regenerative Peripheral Nerve Interfaces (RPNI) surgery in treating symptomatic neuromas of the hand and digits following amputation compared to standard of care using a Prospective, Observational Trial

Medstar Health Research Institute80 participantsStarted Oct 2021

Baltimore, Maryland, United States • Ann Arbor, Michigan, United States

RECRUITINGNA140 miles

ProACT Post-Approval Study

NCT03767595

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Stress Urinary Incontinence

Uromedica145 participantsStarted Feb 2019

Denver, Colorado, United States • Gainesville, Florida, United States • Atlanta, Georgia, United States +3 more locations

Active Not RecruitingPhase 1/2146 miles

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

NCT04093349

The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzyme replacement therapy (ERT). Participants will be treated in sequential, dose-level cohorts.

Pompe DiseasePompe Disease (Late-onset)Glycogen Storage Disease Type 2+4 more

Spark Therapeutics, Inc.4 participantsStarted Oct 2020

Phoenix, Arizona, United States • Orange, California, United States • Atlanta, Georgia, United States +26 more locations

COMPLETEDPhase 3184 miles

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

NCT04233034

Randomized trial of youth aged 7-\<18 years with newly diagnosed stage 3 type 1 diabetes (T1D) to assess the effect of both (1) near-normalization of glucose concentrations achieved through use of a hybrid closed loop (HCL) system and (2) verapamil on preservation of β-cell function 12 months after diagnosis. Participants with body weight ≥30 kg (Cohort A) will be randomly assigned in a factorial design to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. Participants with body weight \<30 kg (Cohort B) will be randomly assigned 2:1 in a parallel group design to HCL plus intensive diabetes management or to usual care with no HCL.

Jaeb Center for Health Research113 participantsStarted Jul 2020

Palo Alto, California, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +3 more locations

COMPLETEDNA274 miles

The PediQUEST Response Intervention Study

NCT03408314

PediQUEST Response proposes a new system of care that expects to improve quality of life in children, adolescents, and young adults with advanced cancer and their parents. The investigators want to learn whether patients that are cared for using PediQUEST Response do in fact feel better than those receiving usual care. National recommendations call for early palliative care (PC) integration for seriously ill children to ease suffering, however, very few randomized controlled trials (RCTs) have evaluated whether PC improves child and family outcomes. In prior work, the investigators developed the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST/PQ), a software that collects electronic Patient-Reported Outcomes (e-PROMS) and generates feedback reports. Now, the PI and research team developed PediQUEST Response (Response to Pediatric Oncology Symptom Experience). PediQUEST Response includes an enhanced PediQUEST system (web-based and with an App that allows to answer surveys and see reports), that is coupled with early integration of a palliative care consulting team (Response team). This dual strategy will help to standardize the family report of distress, which will be done through the PediQUEST system. It will also help standardize the providers' response to such distress, as providers will be specifically trained. Pilot work for PediQUEST Response found it feasible, well received by families and oncologists, and potentially effective. Thus, the overall goal of this study is to conduct a RCT of PQ Response versus usual care at four large pediatric oncology centers among 136 children ≥2 years old with advanced cancer. Hypotheses include a) children receiving the intervention will have better (higher) quality of life scores b) parents of children in the intervention group will report better state-anxiety, depression and symptom-related stress scores, and c) intervention group families will demonstrate higher levels of activation.

Advanced Cancer

Joanne Wolfe, MD, MPH196 participantsStarted Mar 2018

Chicago, Illinois, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +3 more locations

RECRUITINGPhase 1/2306 miles

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

NCT06681688

This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.

Inder Paul Singh, M.D.94 participantsStarted Jul 2024

Venice, Florida, United States • Racine, Wisconsin, United States

COMPLETED322 miles

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

NCT04166149

Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.

Transplant;Failure,KidneyTransplant; Failure, PancreasRejection Acute Renal+1 more

University of Maryland, Baltimore140 participantsStarted Sep 2019

Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States • Madison, Wisconsin, United States

TERMINATEDPhase 1/2322 miles

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

NCT02891161

This is an open label, multi-institutional, single arm study of a phase Ib study, followed by a phase II study of durvalumab with radiation therapy (RT) in patients with urothelial cancer (UC). No randomization or blinding is involved.

Urothelial Cancer

Monika Joshi, MD26 participantsStarted Nov 2016

Iowa City, Iowa, United States • Omaha, Nebraska, United States • New Brunswick, New Jersey, United States +4 more locations

Active Not RecruitingPhase 3364 miles

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT03319667

Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and dexamethasone, in participants with newly diagnosed multiple myeloma (NDMM) not eligible for transplant. Secondary Objectives: * To evaluate in both randomized (isatuximab, bortezomib, lenalidomide and dexamethasone combination (IVRd) and bortezomib, lenalidomide and dexamethasone combination (VRd)) arms: * Complete response (CR) rate, as defined by the International Myeloma Working Group (IMWG) criteria. * Minimal residual disease (MRD) negativity rate in participants with CR. * Very good partial response or better rate, as defined by the IMWG criteria. * Overall survival (OS). * To evaluate the overall response rate (ORR) as per IMWG criteria. * To evaluate the time to progression (TTP) overall and by MRD status. * To evaluate PFS by MRD status. * To evaluate the duration of response (DOR) overall and by MRD status. * To evaluate time to first response (TT1R). * To evaluate time to best response (TTBR). * To evaluate progression-free survival on next line of therapy (PFS2). * To evaluate the sustained MRD negativity \>12 months rate. * To evaluate safety. * To determine the pharmacokinetic (PK) profile of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (IVRd arm only). * To evaluate the immunogenicity of isatuximab in participants receiving isatuximab (IVRd and crossover arms). * To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.

Plasma Cell Myeloma

Sanofi475 participantsStarted Dec 2017

Fort Myers, Florida, United States • St. Petersburg, Florida, United States • Kansas City, Missouri, United States +101 more locations

COMPLETEDNA391 miles

Feasibility Study of the Reia Vaginal Pessary

NCT04508335

The purpose of this study is to obtain preliminary data on the effectiveness, safety, function, comfort, and patient satisfaction with a novel vaginal pessary design for the use in women who suffer from symptoms of pelvic organ prolapse (POP) and have already opted for non-surgical management. Recruited patients will have Stage II POP or greater and will be current users of a Gellhorn or ring style pessary. Following enrollment, each subject will enter a 1-month wash out period in which they will continue using their current pessary so that baseline subjective and objective data can be collected. They will then be fit with a study pessary and enter a 3-month treatment phase. Comparative, subjective, and objective data will be collected at the conclusion of the study.

Pelvic Organ Prolapse

Reia, LLC78 participantsStarted Nov 2021

Birmingham, Alabama, United States • Cambridge, Massachusetts, United States • Lebanon, New Hampshire, United States +4 more locations

Active Not Recruiting460 miles

LEGION Hinge Safety and Efficacy Study

NCT02445443

The purpose of the current investigation is to assess the safety and efficacy of a new hinged revision knee device. This device is designed to provide efficient, reproducible reconstructions with optimal limb and implant alignment, durable implant fixation, and functional outcomes that increasingly approach those of primary Total Knee Arthroplasty (TKA).

Knee Arthroplasty, Total

Smith & Nephew, Inc.47 participantsStarted Jun 2015

Iowa City, Iowa, United States • New York, New York, United States • Portland, Oregon, United States +4 more locations

COMPLETEDPhase 3460 miles

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

NCT04966741

This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) genes or Bardet-Biedl Syndrome (BBS).

Bardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency Obesity+1 more

Rhythm Pharmaceuticals, Inc.12 participantsStarted Mar 2022

Aurora, Colorado, United States • New York, New York, United States • Marshfield, Wisconsin, United States +3 more locations

Active Not RecruitingNA583 miles

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

NCT02730338

To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.

Metastatic Prostate Cancer

Movember Foundation866 participantsStarted Jan 2016

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +15 more locations

RECRUITINGPhase 1583 miles

A Study of SPY002-072 in Healthy Volunteers

NCT06622070

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

Spyre Therapeutics, Inc.56 participantsStarted Nov 2024

Cypress, California, United States • Montreal, Quebec, Canada

PreviousPage 344 of 1047Next

Heart Diseasein Ohio